Press release - ABNewswire - HER2 Negative Metastatic Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects - published on openPR.com
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to.
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data
The WIN-B is a Phase Ib/II investigator-sponsored trial (IST) that will evaluate the safety and preliminary efficacy of the Debiopharm's potent Wee-1 inhibitor Debio 0123 in combination with Gilead's